StockNews.AISignal intelligence
Company intelligence

EPRX

Eupraxia Pharmaceuticals Inc. · NASDAQ · Healthcare

Price$7.75+6.98% · +$0.51
Market cap259.3MEquity value
P / E-8.2Trailing ratio
Volume1.76MLatest session
Market data

EPRX price chart

TradingView
Related signals
1 min delayed

Browse public EPRX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

EPRXMar 23, 2026-6.51% since signal

Eupraxia Pharmaceuticals Rated Outperform with $14 Fair Value Estimate

Eupraxia Pharmaceuticals (EPRX) received an Outperform rating from William Blair, emphasizing its lead drug EP-104GI's potential in treating eosinophilic esophagitis, with promising early trial data. The estimated peak sales potential of over $900 million suggests significant upside for investors, especially with plans to expand into additional GI indications.

View signal analysis
Research

Company intelligence